(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.
"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial," said Andrei Floroiu, CEO of Vaxart.
The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.
Vaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments